Navigation Links
Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
Date:12/2/2008

Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents

WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire/ -- Eisai Corporation of North America today announced that it plans to initiate the first clinical trial evaluating the activity of Dacogen(R) (decitabine for injection) compared to Vidaza(R) (azacitidine) in adult patients with intermediate-1, intermediate-2 or high-risk myelodysplastic syndromes (MDS), a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells. The head-to-head trial will be conducted in the United States and will directly compare Dacogen(R) to Vidaza(R) with a primary endpoint of complete response rate (including marrow complete response).

"Previous to the introduction of the hypomethylating agents, supportive care was the only treatment option for patients living with MDS," said Dr. Hagop M. Kantarjian, chairman of the Leukemia Department and professor of medicine, University of Texas M.D. Anderson Cancer Center. "This study, for the first time, will provide physicians with important information to understand how these two agents compare when treating patients with MDS, who currently have a generally poor prognosis, with life expectancies shorter than those with lung cancer."

Study Design

This randomized, multi-center, open-label study will be conducted among 228 adult patients with intermediate-1, intermediate-2 and high-risk MDS. Patients will be randomized on a 1:1 ratio to either Dacogen(R) or Vidaza(R). Each treatment arm will be stratified by IPSS risk group and type of MDS (primary vs. secondary).

The study's primary objective is to compare the complete response rates, including bone marrow response rates, for Dacogen(R) versus Vidaza(R).

"Findings from this trial could help clarify the fundament
'/>"/>

SOURCE Eisai Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
7. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
8. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
9. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
10. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...ESTER, N.Y., Nov. 27 Pr...provider and fortunately every year, new vaccines ...ut do all vaccines boost immunity for the same per...ster shots, needed to keep immunity strong? ,... of the American Academy of Pediatrics, Michael Pi...
(Date:11/27/2009)... XenaCare Holdings has announced that it ...ndation, one of the largest nonprofit organization...h education. , Delray Bea...ngs, Inc. (OTCBB: XCHO), a company specializing in... healthcare products, has announced today that is ...
(Date:11/27/2009)... , SEATTLE, Nov. 27 Allr...record-high Thanksgiving traffic numbers, with mor...iving, providing a clear picture of what was serve...rage Thanksgiving meal in 2009 weighed in at 2,225...ast year,s feast. According to the Allrecipes site...
(Date:11/27/2009)... Specialist manufacturers who use medical...ing millions of dollars by bringing in technology ...asing numbers of pro-active medical manufacturers ...ncept stage of their projects, ensuring that progr...cesses or potentially outdated technology. , ...
(Date:11/26/2009)...INCETON, N.J., Nov. 27 The diabete...le over the next 25 years and annual medical spend...n, up from $113 billion today, according to a stud...e . The National Changing Diabetes ® Progra...the analysis by a team from the University of Chic...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4
...sive-compulsive disorder has a tendency to affect ...ses severe anxiety// and disturbing thoughts, whic...behaviors. It is estimated that close relatives of...y contribute to that pattern. And while no one gen...
...orkings of the mind are really mysterious, however...t can see through the regions of the brain affecte...earchers feel the program could be worked out even...down. Raymond Deicken at the University of Califor...
...tion Deficit-Hyperactivity Disorder (ADHD) affects...r both of them. Drug users and alcoholics are espe...ms and increases the severity of their addiction. ...t National Development and Research Institutes in ...
...uana dependence and abuse can be moderately improv...ed use rather than abstinence may be the best clin...inds. One-on-one cognitive behavioral thera.... Dr. Marc Auriacombe of the Addiction Resea...
...ding to a research conducted by Satish K. Pillai, ...stdoctoral fellow at the University of California,...n was genetically different from those present in ...on in the HIV envelope gene. The study analysed ab...
...K National Institute for Health and Clinical Excel...ly use biological therapies, Enbrel?// (etanercept...s suffering acute plaque psoriasis. Despite this m...a reprieve for many thousands of patients across U...
Other Medicine News:Health News:Obsessive-Compulsive Disorder Is Familial 2Health News:Obsessive-Compulsive Disorder Is Familial 3Health News:Diagnosing Schizophrenia 2Health News:Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat 2Health News:Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat 3Health News:Mutation in the Envelope Gene May Be the Reason for the Development of HIV Linked Cognitive Decline 2Health News:NICE supports application of advanced biological therapies as treatment option for acute psoriasis 2Health News:NICE supports application of advanced biological therapies as treatment option for acute psoriasis 3Health News:NICE supports application of advanced biological therapies as treatment option for acute psoriasis 4
(Date:11/25/2009)... 25 Hologic, Inc. (Holog...eloper, manufacturer and supplier of premium diagn...cts dedicated to serving the healthcare needs of w...cal Society of North America (RSNA) at McCormick P...009 to highlight our new SecurView(®) DX mult...
(Date:11/25/2009)...zerland, Nov. 25 From November 16...e hearing solutions, presented the second edition ...g on the special needs of the older population. Th...ging and audiology from around the world and more ...eople with hearing loss for an opportunity to shar...
(Date:11/25/2009)..., Nov. 25 For many of th...ly the 27 million living with untreated hearing l... audiologist Cindy Beyer. ,, Dr. Beyer, senior ...erica,s largest hearing care and hearing aids co...stress, frustration, and social isolation, "which ...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 32009 National Ergonomics Conference Schedule Announced Focus on Productivity 26 Profitability With Reduced Workforces All Major Sponsors Renew 26 51893 12009 National Ergonomics Conference Schedule Announced Focus on Productivity 26 Profitability With Reduced Workforces All Major Sponsors Renew 26 51893 2Fat Reduction Market in Europe to Soar Despite Economic Downturn 51890 1Fat Reduction Market in Europe to Soar Despite Economic Downturn 51890 2Chimerix Inc Appoints Kenneth I Moch Chief Operating Officer 13059 1Chimerix Inc Appoints Kenneth I Moch Chief Operating Officer 13059 2
...c. today,announced positive Phase 2 data for the C...ss aminomethylcycline (AMC). The Phase 2 study com...(IV) forms of PTK 0796 to,Zyvox(R) in the treatmen...ture infections (cSSSIs). Paratek,s trial met its ...ating no differences between PTK 0796 and,Zyvox in...
...maceuticals plc (AIM: MPM), the drug development c...c disorders, is pleased to announce positive,resul...t in the prevention,of migraine with aura. The med....01) in patients receiving tonabersat when compare...t of the study is both clinically and,statisticall...
Other Medicine Technology:Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura 2Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura 3
Streck-Lysing Agent III Lytic Reagent
Streck-Hemoglobin/Lyse Lytic Reagent
Streck-Diluent III Plus Balanced Electrolyte Solution
Streck-Detergent III Balanced Electrolyte Solution
Medicine Products: